Maria Stys, MD
Cardiovascular Disease · Sioux Falls, SDNPI 1740493964
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,300 of the $3,390 with a category attached, or 67.8%. 21 manufacturers reported payments, led by Abbott at 44.4% of the total. Reporting peaked in 2019 at $2,196 and has fallen 94.4% since, to $123 in 2025.
Across 64 payments — averaging $52.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Acist Medical Systems, Inc.$546
- Medtronic$404
- Abiomed$323
- Actelion Pharmaceuticals US, Inc.$111
- E.r. Squibb & Sons, L.L.C.$70
- plus $431 from 15 others
What the payments were for
- Travel & lodging$1,09032%
- Food & beverage$2,30068%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $1,505 |
| Acist Medical Systems, Inc. | 3 | $546 |
| Medtronic(2 entities) | 11 | $404 |
| Abiomed | 4 | $323 |
| Actelion Pharmaceuticals US, Inc. | 8 | $111 |
| E.r. Squibb & Sons, L.L.C. | 3 | $70 |
| United Therapeutics Corporation | 4 | $49 |
| Pfizer | 2 | $42 |
| AstraZeneca | 3 | $40 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Cardiovascular Systems Inc. | 1 | $35 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $34 |
| Amgen | 2 | $34 |
| Philips North America LLC | 1 | $28 |
| Boston Scientific | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Novartis | 1 | $20 |
| Bayer | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$1,082
- HD-IVUS$340
- Impella$133
- Xience Sierra Coronary Stent System$132
- CVI SYSTEMS$122
- Euphora$101
How this compares
$3,390 in reported general payments places this provider in the 70th percentile of 33 cardiovascular disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 337 | $318,271 |
| XareltoRivaroxaban | 150 | $138,133 |
| Repatha SureclickEvolocumab | 42 | $28,504 |
| Praluent PenAlirocumab | 11 | $9,976 |
| Metoprolol Succinate | 586 | $7,927 |
| Rosuvastatin Calcium | 222 | $3,046 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 72 | $2,660 |
| Atorvastatin Calcium | 248 | $2,508 |
| Ranolazine ErRanolazine | 26 | $2,331 |
| Ezetimibe | 69 | $2,057 |
| Flecainide Acetate | 22 | $1,253 |
| Spironolactone | 195 | $1,151 |
| Digoxin | 75 | $1,122 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 100 | $931 |
| Amiodarone Hcl | 27 | $904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $42 | $318,271337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 33 cardiovascular disease providers in South Dakota.
Other cardiovascular disease in Sioux Falls
- Naveen RajpurohitSioux Falls$68K
- Kevin VaskaSioux Falls$24K
- Udit BhatnagarSioux Falls$19K
- John BacharachSioux Falls$18K
- Mahmoud SharafSioux Falls$11K
- Christopher PaaSioux Falls$3K
- Richard ClarkSioux Falls$2K
- Amjad Panickaveettil Mohamed BasheerSioux Falls$1K
- Fawzi AmeerSioux Falls$1K
- Sherrie BrooksSioux Falls$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.